Mesa Laboratories - MLAB Stock Forecast, Price & News

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Mesa Laboratories from a "hold" rating to a "sell" rating in a research report on Friday.

Mesa Laboratories Stock Performance

Mesa Laboratories stock traded down $9.58 during mid-day trading on Tuesday, reaching $192.00. The company's stock had a trading volume of 749 shares, compared to its average volume of 35,725. Mesa Laboratories has a 12-month low of $178.32 and a 12-month high of $333.42. The company has a market capitalization of $1.02 billion, a P/E ratio of -671.91 and a beta of 0.52. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.29 and a current ratio of 2.90. The firm's fifty day moving average price is $201.74 and its two-hundred day moving average price is $231.22.

Mesa Laboratories (NASDAQ:MLAB - Get Rating) last released its quarterly earnings results on Thursday, August 4th. The medical instruments supplier reported $0.52 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($1.05). Mesa Laboratories had a negative net margin of 0.78% and a positive return on equity of 5.80%. The firm had revenue of $50.45 million for the quarter, compared to analysts' expectations of $52.63 million. Sell-side analysts predict that Mesa Laboratories will post 7.6 EPS for the current fiscal year.

Mesa Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 15th. Stockholders of record on Wednesday, August 31st will be paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.33%. The ex-dividend date is Tuesday, August 30th. Mesa Laboratories's dividend payout ratio (DPR) is -213.33%.

Insider Activity

In related news, CEO Gary M. Owens sold 1,756 shares of the business's stock in a transaction dated Tuesday, June 21st. The shares were sold at an average price of $188.22, for a total transaction of $330,514.32. Following the transaction, the chief executive officer now owns 21,640 shares in the company, valued at $4,073,080.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director John James Sullivan sold 5,192 shares of the stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $207.76, for a total transaction of $1,078,689.92. Following the sale, the director now owns 23,857 shares in the company, valued at $4,956,530.32. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Gary M. Owens sold 1,756 shares of the stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $188.22, for a total transaction of $330,514.32. Following the transaction, the chief executive officer now owns 21,640 shares in the company, valued at approximately $4,073,080.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,062 shares of company stock valued at $1,618,881. Insiders own 5.50% of the company's stock.